Bio-Rad Laboratories Bilan de santé
Santé financière contrôle des critères 5/6
Bio-Rad Laboratories possède un total de capitaux propres de $7.5B et une dette totale de $1.2B, ce qui porte son ratio d'endettement à 15.9%. Son actif total et son passif total sont $10.6B et de $3.1B. L'EBIT de Bio-Rad Laboratories est $333.9M ce qui fait que son ratio de couverture des intérêts -9.9. Elle dispose de liquidités et de placements à court terme de $1.6B.
Informations clés
15.9%
Ratio d'endettement
US$1.19b
Dette
| Ratio de couverture des intérêts | -9.9x |
| Argent liquide | US$1.62b |
| Fonds propres | US$7.49b |
| Total du passif | US$3.12b |
| Total des actifs | US$10.60b |
Mises à jour récentes de la santé financière
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Recent updates
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet
May 02Analyse de la situation financière
Passif à court terme: Les actifs à court terme de BIO ( $3.1B ) dépassent ses passifs à court terme ( $497.9M ).
Passif à long terme: Les actifs à court terme de BIO ( $3.1B ) dépassent ses passifs à long terme ( $2.6B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: BIO dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de BIO est passé de 8.3% à 15.9% au cours des 5 dernières années.
Couverture de la dette: La dette de BIO est bien couverte par le flux de trésorerie opérationnel ( 34.6% ).
Couverture des intérêts: BIO gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.